Soliqua 100/33 (lixisenatide/insulin glargine) / Zealand Pharma, Sanofi - LARVOL DELTA

IGlarLixi Improves PPG and DTIR in Asian People with T2D (PwT2D): Post Hoc Pooled Analysis of Ph3 Studies (ADA 2026) - "Available on Friday, May 29, 2026 at 12:00am CDT."

Retrospective data • Metabolic Disorders • Type 2 Diabetes Mellitus

Impact of IGlarLixi on Glycemic Variability (GV): A Participant-Level Exploratory Pooled Analysis of the Global LixiLan Clinical Trial Program (ADA 2026) - "Available on Friday, May 29, 2026 at 12:00am CDT."

Retrospective data • Metabolic Disorders

IMPACT OF TIME OF INJECTION COMPARING IGLARLIXI VS IDEGASP IN CHINESE PEOPLE WITH T2D: EXPLORATORY ANALYSIS OF SOLID STUDY (ATTD 2026) - P3 | "iGlarLixi confirmed better glycaemic control and body weight benefits with lower insulin doses and less hypoglycaemia risk vs IDegAsp regardless of IDegAsp injection time. Funded by Sanofi. Previously presented at ADA and EASD."

Hypoglycemia • Type 2 Diabetes Mellitus

EARLY GLYCAEMIC IMPROVEMENT WHEN SWITCHING TO IGLARLIXI FROM PREMIXED INSULINS (PI) IN ADULTS WITH TYPE 2 DIABETES (T2D): A POST HOC ANALYSIS OF SOLI-SWITCH (ATTD 2026) - P4 | "In adults with T2D who switched from PI to iGlarLixi, glycaemic control improved in the first weeks of transitioning (Weeks 0–3) and continued to improve to Week 12. Funded by Sanofi. Previously presented at ADA and EASD"

Clinical • Retrospective data • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

EFFICACY OF IGLARLIXI IN PEOPLE WITH TYPE 2 DIABETES (T2D) BY BMI AT BASELINE: A POST HOC POOLED ANALYSIS OF REAL-WORLD AND CLINICAL TRIAL DATA (ATTD 2026) - "This pooled analysis of iGlarLixi study data found consistent benefits for people with T2D treated with iGlarLixi, regardless of BMI group at baseline."

Real-world • Real-world evidence • Retrospective data • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

IDEGLIRA OR IGLARLIXI GIVEN AFTER SHORT-TERM INTENSIVE INSULIN TREATMENT COMPARED TO BASAL-BOLUS FOR INSULIN-NAIVE TYPE 2 DIABETES PATIENTS WITH SEVERE HYPERGLYCEMIA (ATTD 2026) - "In insulin-naive T2D patients with severe hyperglycemia, FRCs initiated after STII provide similar glucose control as BBT but with less hypoglycemia and a more favorable effect on body weight."

Clinical • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

POST-PRANDIAL GLUCOSE EXCURSIONS WITH IGLARLIXI VERSUS MONOCOMPONENTS AND GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS IN ADULTS WITH TYPE 2 DIABETES: A POST HOC POOLED ANALYSIS (ATTD 2026) - "In this pooled analysis, iGlarLixi demonstrated consistent reductions in post-prandial glucose excursions over a 24-hour period in adults with T2D."

Retrospective data • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

EFFICACY OF DE-ESCALATION FROM MULTIPLE DAILY INJECTIONS TO ONCE-DAILY IGLARLIXI IN ADULTS WITH TYPE 2 DIABETES: A POOLED ANALYSIS OF IDEAL AND SOLI-SWITCH STUDIES (ATTD 2026) - "This pooled analysis suggests there are clinical benefits in transitioning from complex insulin regimens to a once-daily treatment with iGlarLixi. Funded by Sanofi."

Retrospective data • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

EFFICACY OF IGLARLIXI VERSUS IDEGASP IN CHINESE PEOPLE WITH T2D BY HBA1C TARGET AT END-OF-TREATMENT AND BASELINE POSTPRANDIAL GLUCOSE: A POST-HOC ANALYSIS OF SOLI-D STUDY (ATTD 2026) - P3 | "This post-hoc analysis assessed efficacy and safety of iGlarLixi by HbA1c target achievement and number of participants achieving postprandial glucose (PPG) target at end-of-treatment (EOT). In Soli-D (NCT05413369), Phase-3, 24-week study, insulin-naïve Chinese-adults were randomised 1:1 to receive either iGlarLixi or IDegAsp, with metformin±SGLT-2i. More participants receiving iGlarLixi than IDegAsp achieved HbA1c, PPG targets, body-weight benefit and fewer hypoglycaemic events at EOT. Moreover, in people not achieving HbA1c ≤7%, iGlarLixi could be better titrated as the number of hypoglycaemia events was low."

Clinical • Retrospective data • Hypoglycemia • Type 2 Diabetes Mellitus

A LIFETIME COST-UTILITY ANALYSIS OF IGLARLIXI VERSUS IDEGASP IN TYPE 2 DIABETES IN TURKIYE (ISPOR 2026) - "iGlarLixi is a cost-effective option compared to iDegAsp for uncontrolled T2D in Turkiye,delivering additional life years and QALYs at an acceptable cost.Given the favorable cost-effectiveness of iGlarLixi in patients below the current BMI ≥35 reimbursement cutoff,policymakers could broaden their perspective in the reimbursement restrictions to enhance patient access to newer treatments"

HEOR • Cardiovascular • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Efficacy and Safety of Once-Weekly IcoSema Versus Once-Daily IDegLira in People with Type 2 Diabetes: Systematic Literature Review and Network Meta-analysis. (PubMed, Diabetes Ther) - "These results indicate that once-weekly IcoSema is an efficacious treatment option for adults with T2D requiring insulin intensification. IcoSema was associated with improved glycaemic control, weight reduction, and lower hypoglycaemia risk compared with once-daily IDegLira, as well as a reduction in insulin and injection requirements. Weekly IcoSema offers the potential to reduce treatment burden and increase adherence, thereby improving long-term disease control and patient outcomes."

Journal • Retrospective data • Diabetes • Metabolic Disorders • Severe Hypoglycemia • Type 2 Diabetes Mellitus

Metformin provides superior neuroprotective potential compared to semaglutide in preventing diabetes-associated Alzheimer's disease via dual actions. (PubMed, Commun Med (Lond)) - "These findings reveal that diabetes therapies differ in their ability to protect against AD. Metformin shows the strongest potential, supporting its prioritization for targeted studies in people with diabetes who are at high risk of AD, and highlighting the importance of precision medicine in future prevention trials."

Journal • Alzheimer's Disease • CNS Disorders • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Summary of Research: Safety and Effectiveness of Concomitant iGlarLixi and SGLT-2i Use in People with T2D During Ramadan Fasting: A SoliRam Study Sub-analysis. (PubMed, Diabetes Ther) - "No serious adverse events were reported in either group. The sub-analysis concluded that the concomitant iGlarLixi and SGLT-2i therapy, with or without other OADs, was demonstrated to be a safe treatment for people with T2D during Ramadan fasting."

Journal • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes (clinicaltrials.gov) - P4 | N=324 | Not yet recruiting | Sponsor: Yanbing Li | Initiation date: Oct 2025 ➔ Mar 2026

Trial initiation date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Efficacy and safety of iGlarLixi versus standard of care in a real-world adult China population with uncontrolled type 2 Diabetes on oral agents-a pragmatic randomized controlled trial (ChiCTR) - P=N/A | N=1316 | Not yet recruiting | Sponsor: Zhongshan Hospital, Fudan University; Zhongshan Hospital, Fudan University

New trial • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Clinical efficacy of iGlarLixi in patients with T2DM combined with MASLD (ChiCTR) - P=N/A | N=25 | Completed | Sponsor: Drum Tower Hospital Affiliated to Nanjing University Medical School; Drum Tower Hospital Affiliated to Nanjing University Medical School

New trial • Diabetes • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Type 2 Diabetes Mellitus

A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus (clinicaltrials.gov) - P4 | N=105 | Active, not recruiting | Sponsor: Sanofi | Recruiting ➔ Active, not recruiting

Enrollment closed • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents (clinicaltrials.gov) - P4 | N=1316 | Not yet recruiting | Sponsor: Shanghai Zhongshan Hospital

New P4 trial • Real-world evidence • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Insulin therapy DE-intensificAtion with iGlarLixi: A phase 4, open-label, parallel-group randomised controlled trial. (PubMed, Diabetes Obes Metab) - "Insulin therapy simplification from MDI regimen to once-daily iGlarLixi is an efficient and safe treatment option for PwT2D."

Journal • P4 data • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Effects of iGlarLixi Versus iGlar on Liver Fat Content in Patients With Type 2 Diabetes Mellitus Combined With Metabolic Dysfunction-associated Steatotic Liver Disease (clinicaltrials.gov) - P4 | N=36 | Enrolling by invitation | Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

New P4 trial • Diabetes • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Type 2 Diabetes Mellitus

Early Glycemic Control With iGlarLixi Versus IDegAsp in Chinese Adults With Type 2 Diabetes: A Post Hoc Analysis of the Soli-D Study. (PubMed, J Diabetes) - No abstract available

Journal • Retrospective data • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Systematic Literature Review and Network Meta-Analysis of Once-Weekly Icosema With Daily Fixed-Dose Combinations of Basal Insulin and GLP-1 RA in Patients With Type 2 Diabetes After 52 Weeks of Treatment (ISPOR-EU 2025) - "Once-weekly IcoSema was associated with a significantly greater change in HbA1c and body weight after 52 weeks of treatment compared with daily IDegLira, while also demonstrating significantly lower basal insulin dose and level 2 and level 2 or 3 hypoglycaemia rates, in patients with inadequately controlled T2D."

Retrospective data • Review • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

iGlarLixi: A titrateable fixed-ratio combination of basal insulin + GLP-1 receptor agonist-An effective type 2 diabetes treatment option in China. (PubMed, Diabetes Obes Metab) - "iGlarLixi is preferable to premixed insulin and can be combined with OADs among typical people with T2DM and poor glycaemic control. The safety, efficacy, and practical convenience of iGlarLixi are summarised in the Chinese healthcare context."

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A real-world study assessing the efficacy and safety of switching from basal bolus insulin therapy to once daily iGlarLixi in people with type 2 diabetes mellitus: soli de-escalation. (PubMed, Diabetes Res Clin Pract) - "Switching from BBI to once-daily iGlarLixi improved glycemic control with significant HbA1c reduction and fewer hypoglycemic events."

Journal • Real-world evidence • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Efficacy and safety of iGlarLixi versus IDegAsp by baseline β-cell function in Chinese people with type 2 diabetes: Exploratory analyses of the Soli-D study. (PubMed, Diabetes Obes Metab) - "iGlarLixi provides improved glycaemic control at lower insulin daily doses compared with IDegAsp, regardless of C-peptide or HOMA-β levels, in Chinese people with uncontrolled T2D on OADs."

Journal • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus